Smith & Nephew plc (LON:SN - Get Free Report) announced a dividend on Tuesday, February 25th, DividendData.Co.Uk reports. Investors of record on Thursday, March 27th will be paid a dividend of $0.23 per share on Wednesday, May 28th. This represents a yield of 1.61%. The ex-dividend date is Thursday, March 27th. This is a 60.4% increase from Smith & Nephew's previous dividend of $0.14. The official announcement can be viewed at this link.
Smith & Nephew Stock Up 0.4 %
Shares of LON:SN traded up GBX 4 ($0.05) during midday trading on Friday, reaching GBX 1,071 ($13.86). The company's stock had a trading volume of 1,639,303 shares, compared to its average volume of 343,671. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The business has a 50-day moving average of GBX 1,070.03 and a 200 day moving average of GBX 1,052.57. The stock has a market capitalization of £11.74 billion, a price-to-earnings ratio of 38.56, a P/E/G ratio of 0.46 and a beta of 0.62.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. reissued an "overweight" rating and issued a GBX 1,180 ($15.27) target price on shares of Smith & Nephew in a research note on Tuesday, January 14th.
Check Out Our Latest Report on SN
Insider Buying and Selling
In related news, insider Sybella Stanley acquired 3,810 shares of the stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of GBX 1,101 ($14.25) per share, with a total value of £41,948.10 ($54,294.72). 0.19% of the stock is currently owned by insiders.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also

Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.